Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas

Allen M. Chen, M. Kara Bucci, Jeanne M. Quivey, Joaquin Garcia, David W. Eisele, Karen K. Fu

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: To review a single-institution experience with the management of salivary gland cancers treated by radiation alone. Methods and Materials: Between 1960 and 2004, 45 patients with newly diagnosed salivary gland carcinomas were treated with definitive radiation to a median dose of 66 Gy (range, 57-74 Gy). Distribution of T-stage was: 24% T1, 18% T2, 31% T3, and 27% T4. Histology was: 14 mucoepidermoid (31%), 10 adenocarcinoma (22%), 8 adenoid cystic (18%), 4 undifferentiated (9%), 4 acinic (9%), 2 malignant mixed (4%), 2 squamous (4%), and 1 salivary duct carcinoma (2%). No patient had clinical or pathologic evidence of lymph node disease. Median follow-up was 101 months (range, 3-285 months). Results: The 5-year and 10-year rate estimates of local control were 70% and 57%, respectively. A Cox proportional hazard model identified T3-4 disease (p = 0.004) and radiation dose lower than 66 Gy (p = 0.001) as independent predictors of local recurrence. The 10-year overall survival and distant metastasis-free rates were 46% and 67%, respectively. Conclusion: Radiation therapy alone is a reasonable alternative to surgery in the definitive management of salivary gland cancers and results in long-term survival in a significant proportion of patients. Radiation dose in excess of 66 Gy is recommended.

Original languageEnglish (US)
Pages (from-to)1044-1050
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume66
Issue number4
DOIs
StatePublished - Nov 15 2006
Externally publishedYes

Fingerprint

salivary glands
Salivary Glands
radiation therapy
Radiotherapy
cancer
Salivary Gland Neoplasms
Radiation
Carcinoma
radiation
dosage
Salivary Ducts
Adenoids
Survival
histology
lymphatic system
metastasis
ducts
Proportional Hazards Models
surgery
hazards

Keywords

  • Head and neck
  • Radiation therapy
  • Salivary gland cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. / Chen, Allen M.; Bucci, M. Kara; Quivey, Jeanne M.; Garcia, Joaquin; Eisele, David W.; Fu, Karen K.

In: International Journal of Radiation Oncology Biology Physics, Vol. 66, No. 4, 15.11.2006, p. 1044-1050.

Research output: Contribution to journalArticle

Chen, Allen M. ; Bucci, M. Kara ; Quivey, Jeanne M. ; Garcia, Joaquin ; Eisele, David W. ; Fu, Karen K. / Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. In: International Journal of Radiation Oncology Biology Physics. 2006 ; Vol. 66, No. 4. pp. 1044-1050.
@article{c94fe8e256d14c6ea94bacdc9739ed96,
title = "Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas",
abstract = "Purpose: To review a single-institution experience with the management of salivary gland cancers treated by radiation alone. Methods and Materials: Between 1960 and 2004, 45 patients with newly diagnosed salivary gland carcinomas were treated with definitive radiation to a median dose of 66 Gy (range, 57-74 Gy). Distribution of T-stage was: 24{\%} T1, 18{\%} T2, 31{\%} T3, and 27{\%} T4. Histology was: 14 mucoepidermoid (31{\%}), 10 adenocarcinoma (22{\%}), 8 adenoid cystic (18{\%}), 4 undifferentiated (9{\%}), 4 acinic (9{\%}), 2 malignant mixed (4{\%}), 2 squamous (4{\%}), and 1 salivary duct carcinoma (2{\%}). No patient had clinical or pathologic evidence of lymph node disease. Median follow-up was 101 months (range, 3-285 months). Results: The 5-year and 10-year rate estimates of local control were 70{\%} and 57{\%}, respectively. A Cox proportional hazard model identified T3-4 disease (p = 0.004) and radiation dose lower than 66 Gy (p = 0.001) as independent predictors of local recurrence. The 10-year overall survival and distant metastasis-free rates were 46{\%} and 67{\%}, respectively. Conclusion: Radiation therapy alone is a reasonable alternative to surgery in the definitive management of salivary gland cancers and results in long-term survival in a significant proportion of patients. Radiation dose in excess of 66 Gy is recommended.",
keywords = "Head and neck, Radiation therapy, Salivary gland cancer",
author = "Chen, {Allen M.} and Bucci, {M. Kara} and Quivey, {Jeanne M.} and Joaquin Garcia and Eisele, {David W.} and Fu, {Karen K.}",
year = "2006",
month = "11",
day = "15",
doi = "10.1016/j.ijrobp.2006.06.050",
language = "English (US)",
volume = "66",
pages = "1044--1050",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas

AU - Chen, Allen M.

AU - Bucci, M. Kara

AU - Quivey, Jeanne M.

AU - Garcia, Joaquin

AU - Eisele, David W.

AU - Fu, Karen K.

PY - 2006/11/15

Y1 - 2006/11/15

N2 - Purpose: To review a single-institution experience with the management of salivary gland cancers treated by radiation alone. Methods and Materials: Between 1960 and 2004, 45 patients with newly diagnosed salivary gland carcinomas were treated with definitive radiation to a median dose of 66 Gy (range, 57-74 Gy). Distribution of T-stage was: 24% T1, 18% T2, 31% T3, and 27% T4. Histology was: 14 mucoepidermoid (31%), 10 adenocarcinoma (22%), 8 adenoid cystic (18%), 4 undifferentiated (9%), 4 acinic (9%), 2 malignant mixed (4%), 2 squamous (4%), and 1 salivary duct carcinoma (2%). No patient had clinical or pathologic evidence of lymph node disease. Median follow-up was 101 months (range, 3-285 months). Results: The 5-year and 10-year rate estimates of local control were 70% and 57%, respectively. A Cox proportional hazard model identified T3-4 disease (p = 0.004) and radiation dose lower than 66 Gy (p = 0.001) as independent predictors of local recurrence. The 10-year overall survival and distant metastasis-free rates were 46% and 67%, respectively. Conclusion: Radiation therapy alone is a reasonable alternative to surgery in the definitive management of salivary gland cancers and results in long-term survival in a significant proportion of patients. Radiation dose in excess of 66 Gy is recommended.

AB - Purpose: To review a single-institution experience with the management of salivary gland cancers treated by radiation alone. Methods and Materials: Between 1960 and 2004, 45 patients with newly diagnosed salivary gland carcinomas were treated with definitive radiation to a median dose of 66 Gy (range, 57-74 Gy). Distribution of T-stage was: 24% T1, 18% T2, 31% T3, and 27% T4. Histology was: 14 mucoepidermoid (31%), 10 adenocarcinoma (22%), 8 adenoid cystic (18%), 4 undifferentiated (9%), 4 acinic (9%), 2 malignant mixed (4%), 2 squamous (4%), and 1 salivary duct carcinoma (2%). No patient had clinical or pathologic evidence of lymph node disease. Median follow-up was 101 months (range, 3-285 months). Results: The 5-year and 10-year rate estimates of local control were 70% and 57%, respectively. A Cox proportional hazard model identified T3-4 disease (p = 0.004) and radiation dose lower than 66 Gy (p = 0.001) as independent predictors of local recurrence. The 10-year overall survival and distant metastasis-free rates were 46% and 67%, respectively. Conclusion: Radiation therapy alone is a reasonable alternative to surgery in the definitive management of salivary gland cancers and results in long-term survival in a significant proportion of patients. Radiation dose in excess of 66 Gy is recommended.

KW - Head and neck

KW - Radiation therapy

KW - Salivary gland cancer

UR - http://www.scopus.com/inward/record.url?scp=33750308977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750308977&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2006.06.050

DO - 10.1016/j.ijrobp.2006.06.050

M3 - Article

VL - 66

SP - 1044

EP - 1050

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -